The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as first-line treatment of treat adult and pediatric patients aged 12 years and older who have unresectable or metastatic colorectal cancer characterized by microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) biomarkers.
Expanded Approval for Nivolumab Alone
In addition to the combination therapy, the FDA converted the previous accelerated approval for single-agent nivolumab into regular approval. Nivolumab can now be used for patients with MSI-H or dMMR metastatic colorectal cancer that has progressed after treatments with fluoropyrimidine, oxaliplatin, and irinotecan.
Clinical Trial Evidence
The approval is based on findings from the Phase 3 CheckMate-8HW trial, which is the largest study to date evaluating immunotherapy in MSI-H/dMMR colorectal cancer patients. The trial demonstrated that the combination of nivolumab and ipilimumab significantly improved progression-free survival compared to chemotherapy in first-line treatment settings. It also showed benefits over nivolumab alone across all treatment lines.
Key results include:
- First-line setting: Median progression-free survival (PFS) was not reached in patients receiving nivolumab + ipilimumab, compared to 5.8 months for those on chemotherapy (hazard ratio: 0.21; p-value <0.0001).
- All treatment lines: Median PFS was longer with nivolumab + ipilimumab (not reached) versus nivolumab alone (39.3 months; hazard ratio: 0.62; p-value 0.0003).
Common Side Effects
Patients treated with the combination therapy commonly reported side effects such as fatigue, diarrhea, abdominal pain, pruritus (itching), musculoskeletal pain, and nausea. These reactions were consistent with those observed in previous studies of immunotherapy drugs.
What This Means for Patients
This approval provides new options for patients with advanced colorectal cancer with MSI-H or dMMR biomarkers. Immunotherapy has proven to be a game-changer in these cases, offering improved survival outcomes compared to traditional chemotherapy options.
More Reading
Understanding MSI-High and DNA Mismatch Repair (dMMR)
Treatment & Management of Colon Cancer
Precision Cancer Medicine for Colon Cancer
Join the conversation on Cancer Connect
References:
